课题基金 / 基金详情

Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1

Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1
评估基于 Proviral DNA 的抗逆转录病毒耐药性检测在 1 型人类免疫缺陷病毒感染者中的临床效用
批准号：
449333
负责人：
Sudderuddin K Hanwei
金额：
$1.27万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-12-01 至 2021-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449333&lang=en
关键词：
Antiretroviral Therapy Archived Proviral Hiv Dna Genotype Bioinformatics Biostatistics Hiv Antiretroviral Treatment Guidelines Hiv Drug Resistance Hiv-1 Hiv-1 Proviral Dna Hiv-1 Proviral Dna Resistance Testing Next-Generation Sequencing

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Globally, Human Immunodeficiency Virus (HIV) infects 38 million people, including over 68,000 Canadians. These individuals must take antiretroviral therapy (ART) that blocks HIV replication and thereby significantly improves quality and duration of life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文